See more : First Republic Corporation of America (The) (FRPC) Income Statement Analysis – Financial Results
Complete financial analysis of TaiMed Biologics Inc. (4147.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TaiMed Biologics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Wuyi Co., Ltd. (000797.SZ) Income Statement Analysis – Financial Results
- Servicios Corporativos Javer, S.A.B. de C.V. (JAVER.MX) Income Statement Analysis – Financial Results
- Hangzhou Prevail Optoelectronic Equipment Co., Ltd. (300710.SZ) Income Statement Analysis – Financial Results
- Noritz Corporation (NRTZF) Income Statement Analysis – Financial Results
- CM Life Sciences II Inc. (CMIIW) Income Statement Analysis – Financial Results
TaiMed Biologics Inc. (4147.TWO)
About TaiMed Biologics Inc.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 491.78M | 563.01M | 413.44M | 722.49M | 704.50M | 241.04M | 8.44M | 2.08M | 0.00 | 0.00 | 0.00 | 0.00 | 135.00K | 0.00 | 0.00 |
| Cost of Revenue | 266.54M | 347.30M | 329.49M | 401.24M | 474.49M | 260.90M | 0.00 | 3.49M | 3.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 225.23M | 215.71M | 83.96M | 321.24M | 230.01M | -19.86M | 8.44M | -1.41M | -3.43M | 0.00 | 0.00 | 0.00 | 135.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 45.80% | 38.31% | 20.31% | 44.46% | 32.65% | -8.24% | 100.00% | -67.97% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 294.28M | 333.12M | 460.60M | 394.45M | 575.83M | 440.39M | 510.74M | 276.61M | 442.46M | 249.83M | 233.05M | 224.45M | 222.56M | 268.96M | 206.91M |
| General & Administrative | 55.10M | 50.31M | 46.59M | 43.05M | 44.17M | 42.61M | 42.92M | 38.37M | 48.68M | 45.73M | 24.41M | 19.91M | 18.35M | 13.62M | 14.24M |
| Selling & Marketing | 42.08M | 24.14M | 63.13M | 16.50M | 0.00 | 16.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 97.19M | 74.45M | 109.72M | 59.55M | 44.17M | 42.63M | 42.92M | 38.37M | 48.68M | 45.73M | 24.41M | 19.91M | 18.35M | 13.62M | 14.24M |
| Other Expenses | 0.00 | -71.67M | 18.85M | -54.94M | -188.30M | -925.00K | 20.66M | 30.94M | -19.46M | -16.15M | -5.78M | 31.36M | 30.61M | 38.34M | 5.93M |
| Operating Expenses | 391.46M | 407.57M | 570.32M | 454.00M | 620.01M | 300.93M | 553.65M | 314.97M | 471.68M | 279.41M | 251.68M | 244.36M | 240.91M | 282.58M | 221.15M |
| Cost & Expenses | 658.01M | 754.86M | 899.81M | 855.25M | 1.09B | 561.83M | 553.65M | 314.97M | 471.68M | 279.41M | 251.68M | 244.36M | 240.91M | 282.58M | 221.15M |
| Interest Income | 8.36M | 4.34M | 4.03M | 8.48M | 14.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.54M | 6.33M | 4.83M | 1.92M |
| Interest Expense | 14.81M | 10.10M | 7.44M | 4.09M | 356.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 154.76M | 155.82M | 156.04M | 139.16M | 91.60M | 62.81M | 3.79M | 3.49M | 3.43M | 23.35M | 22.76M | 68.32M | 68.03M | 67.68M | 58.70M |
| EBITDA | -25.23M | -103.37M | -307.45M | -40.06M | -486.70M | -258.91M | -541.43M | -309.41M | -487.71M | -256.06M | -228.92M | -145.18M | -172.74M | -214.90M | -163.62M |
| EBITDA Ratio | -5.13% | -18.25% | -74.21% | -5.46% | -68.95% | -106.98% | -6,418.09% | -14,904.19% | 0.00% | 0.00% | 0.00% | 0.00% | -127,958.52% | 0.00% | 0.00% |
| Operating Income | -166.23M | -259.19M | -463.49M | -179.22M | -578.30M | -320.79M | -545.22M | -312.90M | -471.68M | -279.41M | -251.68M | -244.36M | -240.78M | -282.58M | -221.15M |
| Operating Income Ratio | -33.80% | -46.04% | -112.10% | -24.81% | -82.09% | -133.08% | -6,462.97% | -15,072.16% | 0.00% | 0.00% | 0.00% | 0.00% | -178,351.85% | 0.00% | 0.00% |
| Total Other Income/Expenses | -28.58M | -77.43M | 15.43M | -4.09M | -188.66M | -925.00K | 20.66M | 30.94M | 19.46M | 0.00 | 5.78M | 76.52M | 36.26M | 44.37M | 332.00K |
| Income Before Tax | -194.81M | -269.29M | -470.93M | -183.30M | -578.65M | -321.71M | -524.55M | -281.96M | -471.68M | -279.41M | -251.68M | -207.30M | -204.52M | -238.21M | -220.82M |
| Income Before Tax Ratio | -39.61% | -47.83% | -113.91% | -25.37% | -82.14% | -133.47% | -6,218.04% | -13,581.98% | 0.00% | 0.00% | 0.00% | 0.00% | -151,496.30% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.10M | 7.44M | 4.09M | 356.00K | -925.00K | 0.00 | 0.00 | 19.46M | 2.33M | 5.78M | 0.00 | 0.00 | 0.00 | 6.32M |
| Net Income | -194.81M | -279.39M | -478.38M | -187.39M | -579.01M | -321.71M | -524.55M | -281.96M | -471.68M | -281.74M | -251.68M | -207.30M | -204.52M | -238.21M | -220.82M |
| Net Income Ratio | -39.61% | -49.62% | -115.71% | -25.94% | -82.19% | -133.47% | -6,218.04% | -13,581.98% | 0.00% | 0.00% | 0.00% | 0.00% | -151,496.30% | 0.00% | 0.00% |
| EPS | -0.76 | -1.09 | -1.87 | -0.73 | -2.26 | -1.28 | -2.10 | -1.14 | -2.16 | -1.22 | -1.30 | -1.07 | -1.06 | -1.34 | -2.20 |
| EPS Diluted | -0.76 | -1.09 | -1.87 | -0.73 | -2.26 | -1.28 | -2.10 | -1.14 | -2.16 | -1.22 | -1.30 | -1.07 | -1.06 | -1.34 | -2.20 |
| Weighted Avg Shares Out | 256.50M | 256.04M | 255.94M | 255.87M | 255.69M | 250.74M | 249.79M | 247.34M | 218.04M | 231.74M | 194.00M | 193.14M | 193.06M | 177.18M | 100.58M |
| Weighted Avg Shares Out (Dil) | 256.50M | 256.04M | 255.94M | 255.87M | 255.69M | 250.74M | 250.22M | 248.37M | 218.04M | 231.74M | 194.00M | 193.14M | 193.06M | 177.18M | 100.58M |
Source: https://incomestatements.info
Category: Stock Reports